CA3106787A1 - Utilisation d'amphotericine b dans le traitement de maladies du coronavirus - Google Patents

Utilisation d'amphotericine b dans le traitement de maladies du coronavirus Download PDF

Info

Publication number
CA3106787A1
CA3106787A1 CA3106787A CA3106787A CA3106787A1 CA 3106787 A1 CA3106787 A1 CA 3106787A1 CA 3106787 A CA3106787 A CA 3106787A CA 3106787 A CA3106787 A CA 3106787A CA 3106787 A1 CA3106787 A1 CA 3106787A1
Authority
CA
Canada
Prior art keywords
amphotericin
fatty acid
esters
formulation
polyethylene oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3106787A
Other languages
English (en)
Inventor
Kishor M. Wasan
Peter Hnik
Ellen Wasan
Chris GALLIANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amphotericin B Technologies Inc
Original Assignee
Amphotericin B Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amphotericin B Technologies Inc filed Critical Amphotericin B Technologies Inc
Priority to CA3106787A priority Critical patent/CA3106787A1/fr
Priority to PCT/US2022/013411 priority patent/WO2022159767A1/fr
Publication of CA3106787A1 publication Critical patent/CA3106787A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3106787A 2021-01-22 2021-01-22 Utilisation d'amphotericine b dans le traitement de maladies du coronavirus Pending CA3106787A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3106787A CA3106787A1 (fr) 2021-01-22 2021-01-22 Utilisation d'amphotericine b dans le traitement de maladies du coronavirus
PCT/US2022/013411 WO2022159767A1 (fr) 2021-01-22 2022-01-21 Utilisation d'amphotéricine b dans le traitement de maladies à coronavirus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3106787A CA3106787A1 (fr) 2021-01-22 2021-01-22 Utilisation d'amphotericine b dans le traitement de maladies du coronavirus

Publications (1)

Publication Number Publication Date
CA3106787A1 true CA3106787A1 (fr) 2022-07-22

Family

ID=82482522

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3106787A Pending CA3106787A1 (fr) 2021-01-22 2021-01-22 Utilisation d'amphotericine b dans le traitement de maladies du coronavirus

Country Status (2)

Country Link
CA (1) CA3106787A1 (fr)
WO (1) WO2022159767A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217434D0 (en) * 2002-07-27 2002-09-04 Royal Vetinary College Biological material
JP2022507451A (ja) * 2018-11-15 2022-01-18 ブルーウィロー バイオロジクス、インコーポレイテッド 強化された透過性を有するナノエマルジョン組成物
US11629196B2 (en) * 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Also Published As

Publication number Publication date
WO2022159767A1 (fr) 2022-07-28

Similar Documents

Publication Publication Date Title
EP0863765B1 (fr) Compositions pharmaceutiques a base de cyclosporine comportant un acide gras hydroxyle, sature et polyethoxyle
US20150283242A1 (en) Effective pharmaceutical carrier for poorly bioavailable drugs
CZ266399A3 (cs) Tvrdá želatinová tobolka obsahující cyklosporin A
RU2266121C2 (ru) Спонтанно диспергирующиеся композиции, содержащие n-бензоилстауроспорин
US9549918B2 (en) Stabilized tacrolimus composition
KR20070046819A (ko) 지질 부형제의 자가 유화 혼합물의 갈레노스 용도
MX2009000843A (es) Composiciones de ciclosporina.
EA032766B1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
US20080286373A1 (en) Ziprasidone formulations
KR20160029866A (ko) 치료제의 경구 투여를 위한 제제 및 관련 방법
CZ20031407A3 (cs) Farmaceutický prostředek s obsahem pyranonové sloučeniny
CN112168781B (zh) 他克莫司的自微乳组合物及其制备方法
KR20140046395A (ko) 경구 투여를 위한 선택적 인자 ｘａ 억제제의 제약 조성물
KR101821441B1 (ko) 비타민 d의 14-에피-유사체의 새로운 제제
CA3106787A1 (fr) Utilisation d'amphotericine b dans le traitement de maladies du coronavirus
US20240115588A1 (en) Use of proteasome inhibitors in the treatment of coronavirus infections
KR101859200B1 (ko) 모노아세틸디아실글리세롤 화합물의 경구 투여용 조성물 및 고형 제제
US8673866B2 (en) Stabilized formulation for oral administration of therapeutic agents and related methods
CA3104457A1 (fr) Utilisation d'amphotericine b dans le traitement de maladies du coronavirus
US20230101012A1 (en) Stabilized tacrolimus composition
KR20220124891A (ko) 나파모스타트 또는 이의 염을 포함하는 에멀젼을 포함하는 약제학적 제제 및 이의 제조 방법
CN115804753A (zh) 阿戈美拉汀自微乳组合物、胶囊剂及其应用
MXPA01008293A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
AU2006277879A1 (en) Microparticle compositions of the topoisomerase I inhibitor 7-tert-butoxyiminomethylcamptothecin